Differential reactivity to IMPDH2 by anti-rods/rings autoantibodies and unresponsiveness to pegylated interferon-alpha/ribavirin therapy in US and Italian HCV patients

Journal of Clinical Immunology

Volumn 33, Issue 2, 2013, Pages 420-426

  Carcamo, Wendy C ^a   Ceribelli, Angela ^a   Calise, S John ^a   Krueger, Claire ^a   Liu, Chen ^b   Daves, Massimo ^c   Villalta, Danilo ^d   Bizzaro, Nicola ^e   Satoh, Minoru ^b   Chan, Edward K L ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c GENERAL HOSPITAL   (Italy)

^d S MARIA DEGLI ANGELI HOSPITAL   (Italy)

^e San Antonio Hospital   (Italy)

Author keywords

Autoantibody; Hepatitis C; IMPDH2

Indexed keywords

AUTOANTIBODY; INOSINATE DEHYDROGENASE; INOSINE MONOPHOSPHATE DEHYDROGENASE 2; INOSINE MONOPHOSPHATE DEHYDROGENASE 2 ANTIBODY; PEGINTERFERON ALPHA; RIBAVIRIN; RODS AND RINGS ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG RESPONSE; FEMALE; HEPATITIS C; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RELAPSE; UNITED STATES;

EID: 84879889348     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-012-9827-4     Document Type: Article

References (26)

1. van Regenmortel MH, Mayo MA, Fauquet CM, Maniloff J. Virus nomenclature: consensus versus chaos. Arch Virol. 2000;145:2227-32.
2. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244:359-62.
3. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology. 2002;36:S21-9.
4. Ikeda K, Saitoh S, Koida I, Arase Y, Tsubota A, Chayama K, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology. 1993;18:47-53.
5. Houghton M, Abrignani S. Prospects for a vaccine against the hepatitis C virus. Nature. 2005;436:961-6.
6. Bartenschlager R, Frese M, Pietschmann T. Novel insights into hepatitis C virus replication and persistence. Adv Virus Res. 2004;63:71-180.
7. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol. 2007;5:453-63.
8. Simmonds P. Variability of hepatitis C virus. Hepatology. 1995;21:570-83.
9. Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology. 2005;42:962-73.
10. Ibarra KD, Jain MK, Pfeiffer JK. Host-based ribavirin resistance influences hepatitis C virus replication and treatment response. J Virol. 2011;85:7273-83.
11. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335-74.
12. Ferri S, Muratori L, Lenzi M, Granito A, Bianchi FB, Vergani D. HCV and autoimmunity. Curr Pharm Des. 2008;14:1678-85.
13. Manns MP, Rambusch EG. Autoimmunity and extrahepatic manifestations in hepatitis C virus infection. J Hepatol. 1999;31 Suppl 1:39-42.
14. Zignego AL, Brechot C. Extrahepatic manifestations of HCV infection: facts and controversies. J Hepatol. 1999;31:369-76.
15. Lenzi M, Bellentani S, Saccoccio G, Muratori P, Masutti F, Muratori L, et al. Prevalence of non-organ-specific autoantibodies and chronic liver disease in the general population: a nested case-control study of the Dionysos cohort. Gut. 1999;45:435-41.
16. Clifford BD, Donahue D, Smith L, Cable E, Luttig B, Manns M, et al. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology. 1995;21:613-9.
17. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, et al. Binding of hepatitis C virus to CD81. Science. 1998;282:938-41.
18. Tan EM. Autoantibodies in pathology and cell biology. Cell. 1991;67:841-2.
19. Satoh M, Vazquez-Del Mercado M, Chan EKL. Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases. Mod Rheumatol. 2009;19:219-28.
20. Muratori P, Muratori L, Guidi M, Granito A, Susca M, Lenzi M, et al. Clinical impact of non-organ-specific autoantibodies on the response to combined antiviral treatment in patients with hepatitis C. Clin Infect Dis. 2005;40:501-7.
21. Cassani F, Cataleta M, Valentini P, Muratori P, Giostra F, Francesconi R, et al. Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile. Hepatology. 1997;26:561-6.
22. Gatselis NK, Georgiadou SP, Koukoulis GK, Tassopoulos N, Zachou K, Liaskos C, et al. Clinical significance of organ-and non-organ-specific autoantibodies on the response to anti-viral treatment of patients with chronic hepatitis C. Aliment Pharmacol Ther. 2006;24:1563-73.
23. Carcamo WC, Satoh M, Kasahara H, Terada N, Hamazaki T, Chan JY, et al. Induction of cytoplasmic rods and rings structures by inhibition of the CTP and GTP synthetic pathway in mammalian cells. PLoS One. 2011;6:e29690.
24. Covini G, Carcamo WC, Bredi E, von Muhlen CA, Colombo M, Chan EKL. Cytoplasmic rods and rings autoantibodies developed during pegylated interferon and ribavirin therapy in patients with chronic hepatitis C. Antivir Ther. 2012;17:805-11.
25. Satoh M, Langdon JJ, Hamilton KJ, Richards HB, Panka D, Eisenberg RA, et al. Distinctive immune response patterns of human and murine autoimmune sera to U1 small nuclear ribonucleoprotein C protein. J Clin Invest. 1996;97:2619-26.
26. Seelig HP, Appelhans H, Bauer O, Bluthner M, Hartung K, Schranz P, et al. Autoantibodies against inosine-5′-monophosphate dehydrogenase 2-characteristics and prevalence in patients with HCV-infection. Clin Lab. 2011;57:753-65.